Announce top-line results from the ADVANCE-2 study of pimavanserin
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 27 Feb 2024
- Due
- 31 Mar 2024
- Delivered
- March 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We look forward to announcing top-line results from our ADVANCE-2 study of pimavanserin for the negative symptoms of schizophrenia by the end of the first quarter.”
What we found
Evidence strength A What the grades mean
The company announced the top-line results of the ADVANCE-2 study in March 2024, which falls within the first quarter deadline.
-
A Acadia Pharmaceuticals Inc. 10-Q filed 2024-05-09
“In March 2024, we announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.” ✓ confirmed on the page
Market reaction: the shares moved -12.1% against the S&P 500 over the three sessions around the disclosure (8 May 2024 to 13 May 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Announce
- Deliverable
- ADVANCE-2 study top-line results
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-ACAD-002589 · Corrections policy